Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) EBITDA (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed EBITDA for 2 consecutive years, with -$16.5 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 43.0% to -$16.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$99.5 million through Dec 2025, up 21.86% year-over-year, with the annual reading at -$99.5 million for FY2025, 21.86% up from the prior year.
  • EBITDA hit -$16.5 million in Q4 2025 for Prelude Therapeutics, up from -$19.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$16.5 million in Q4 2025 to a low of -$34.8 million in Q2 2024.